TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
Delayed Japan Exchange  -  05/20 02:00:00 am EDT
3729.00 JPY   +1.30%
05/12Japan Index Ends in Red; Toyota Clocks Record-High FY22 Attributable Income but Projects Decline Next Fiscal
MT
05/11Takeda Pharmaceutical's FY22 Attributable Profit Falls 39%
MT
05/11GLOBAL MARKETS LIVE : Coinbase, Roblox, Apple, EA, Hasbro...
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Most relevant news about TAKEDA PHARMACEUTICAL COMPANY LIMITED
05/12Japan Index Ends in Red; Toyota Clocks Record-High FY22 Attributable Income but Project..
MT
05/11Takeda Pharmaceutical's FY22 Attributable Profit Falls 39%
MT
05/11GLOBAL MARKETS LIVE : Coinbase, Roblox, Apple, EA, Hasbro...
05/11TRANSCRIPT : Takeda Pharmaceutical Company Limited, Q4 2022 Earnings Call, May 11, 2022
CI
05/11TRANSCRIPT : Takeda Pharmaceutical Company Limited, 2022 Earnings Call, May 11, 2022
CI
05/11Takeda Pharmaceutical Posts Higher Profit, Revenue in Fiscal 2021
MT
05/11Takeda Pharmaceutical Posted Fourth-Quarter Net Loss
DJ
05/11Takeda Delivers Strong FY2021 Results; Continued Growth Momentum Expected in FY2022
BU
05/11Takeda Pharmaceutical Company Limited Provides Consolidated Earnings Guidance for the F..
CI
05/11Takeda Pharmaceutical Company Limited Declares Dividend for the Year Ended March 31, 20..
CI
05/11Takeda Pharmaceutical Company Limited Reports Earnings Results for the Full Year Ended ..
CI
04/29OncoSec Medical Names Robert Arch CEO; Shares Rise Early
MT
04/29HilleVax Shares Gain Ground in Trading Debut After Upsized IPO
DJ
04/28CENTOGENE and Takeda Extend Market Access and Expansion Partnership to Advance Patient ..
AQ
04/27Takeda Recognized as 2022 ISPE Facility of the Year Awards Winner in Two Categories
AQ
04/26Takeda Holds Fourth Quarter and Full-Year FY2021 Earnings Call on May 11
AQ
04/26Takeda Recognized as the 2022 ISPE Facility of the Year Awards Winner in Two Categories
BU
04/25TAKEDA PHARMACEUTICAL : Holds Fourth Quarter and Full-Year FY2021 Earnings Call on May 1
PU
04/25HilleVax Sets IPO at 10.3 Million Shares; Sees Pricing at $16-$18
DJ
04/22Takeda Pharmaceutical Says Livtencity Treatment Reduces Hospitalizations in Transplant ..
MT
04/22Takeda Presents New Exploratory Analysis Showing Patients Treated With LIVTENCITY&trade..
BU
04/20Takeda to Manufacture Novavax's COVID-19 Vaccine Following Government Approval and Purc..
MT
04/19Novavax Shares Fall 1% Following Nuvaxovid Approval in Japan
DJ
04/19Takeda's TAKHZYRO (lanadelumab-flyo) Prefilled Syringe Now Available for People With He..
AQ
04/19Finch Therapeutics to Cut 20% of Staff in Restructuring
DJ
04/19CORRECTION : Takeda Pharmaceutical's COVID-19 Vaccine Nuvaxovid Gets Approval in Japan
MT
04/19Takeda Pharmaceutical's COVID-19 Vaccine Nuvaxoid Gets Approval in Japan
MT
04/18Takeda Announces Approval of Nuvaxovid® COVID-19 Vaccine for Primary and Booster Immuni..
BU
04/18Takeda Announces Approval of Nuvaxovid Covid-19 Vaccine for Primary and Booster Immuniz..
CI
04/18Takeda Pharmaceutical's Prefilled Takhzyro Syringe Now Available in US
MT
04/18Takeda's TAKHZYRO® (lanadelumab-flyo) Prefilled Syringe Now Available for People With H..
BU
04/18Takeda’s TAKHZYRO® (lanadelumab-flyo) Prefilled Syringe Now Available for People W..
CI
04/14Takeda Pharmaceutical Closes $797 Million Share Buyback
MT
04/13Takeda Announces Completion of Acquisition of Own Shares
BU
04/13Tranche Update on Takeda Pharmaceutical Company Limited's Equity Buyback Plan announced..
CI
04/12Takeda Says Phase 3 Trial of Takhzyro in Pediatric Hereditary Angioedema Meets Safety, ..
MT
04/12Takeda's TAKHZYRO® (lanadelumab) Open Label Phase 3 Study Met Its Objectives in Childre..
BU
04/12Takeda’s Takhzyro® (Lanadelumab) Open Label Phase 3 Study Met Its Objectives in Ch..
CI
04/12TAKEDA : Pediatric Hereditary Angioedema Study Meets Objectives
DJ
04/12Takeda Pharmaceutical Company Limited 's Equity Buyback announced on October 28, 2021, ..
CI
04/09Exclusive Speaker Interview with Ester Lovsin Barle Ahead of the 6th Annual Highly Pote..
AQ
04/06Evozyne Partners With Takeda Pharmaceutical to Develop Gene Therapies
MT
04/05Takeda and the New York Academy of Sciences Announce 2022 Innovators in Science Award W..
BU
04/04Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
AQ
04/01Takeda Pharmaceutical Company Limited Announces Executive Changes
CI
04/01Australian Shares Post Small Loss Amid Decline in Business Confidence
MT
04/01Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
BU
04/01Tranche Update on Takeda Pharmaceutical Company Limited's Equity Buyback Plan announced..
CI
04/01Takeda Pharmaceutical Company Limited acquired A-Digital, Inc.
CI
03/31Hasten Biopharmaceutic Co., Ltd. completed the acquisition of A Portfolio of Five Selec..
CI
03/30Japan Index Comes under Pressure; JCR Pharmaceuticals and Takeda Sign Licensing and All..
MT
03/30TAKEDA PHARMACEUTICAL COMPANY LIMITE : Ex-dividend day for final dividend
FA
03/29Takeda's TAKHZYRO (lanadelumab) Approved in Japan for Prophylaxis Against Acute Attacks..
AQ
03/29JCR Pharmaceuticals and Takeda Sign Licensing and Alliance Deal for Gene Therapies Deve..
MT
03/28Takeda Pharma Secures Approval for Takhzyro to Prevent Hereditary Angioedema in Japan
MT
03/28Takeda's TAKHZYRO® (lanadelumab) Approved in Japan for Prophylaxis Against Acute Attack..
BU
03/28Takeda Receives Approval from the Ministry of Health, Labour and Welfare for TAKHZYRO
CI
03/28U.S. FDA approves UCB's drug for rare childhood epilepsy
RE
03/23COVID vaccine maker Moderna flags Japan ambition with sumo sponsorship
RE
03/22What you need to know about the coronavirus right now
RE
03/22Former Takeda vaccine chief to lead new COVID antiviral venture Aerium
RE
03/22Takeda Provides Natpara U.S. Regulatory Update
CI
03/10Japan considers offering fourth COVID vaccine shot - Yomiuri
RE
03/09Denali Therapeutics Initiates Phase 1/2 Clinical Trial of DNL593 to Treat Frontotempora..
MT
03/08TRANSCRIPT : Takeda Pharmaceutical Company Limited Presents at 42nd Annual Cowen Health Ca..
CI
03/07COVID SCIENCE-Omicron infections contagious for at least 6 days; Takeda drug shows prom..
RE
03/01Takeda - Interim Phase 4 Data Support TAKHZYRO (lanadelumab) as an Effective Treatment ..
AQ
02/28Interim Phase 4 Data Support TAKHZYRO® (lanadelumab) as an Effective Treatment to Reduc..
BU
02/28Takeda Announces Interim Phase 4 Data Support Takhzyro® (Lanadelumab) as an Effective T..
CI
02/22Code Biotherapeutics, Inc. Announces Collaboration with Takeda to Use Proprietary 3Dna ..
CI
02/21Takeda - Alofisel(darvadstrocel) Shows Clinical Remission Rate at Six-Months in the Rea..
AQ
02/18Alofisel®▼ (darvadstrocel) Shows Clinical Remission Rate at Six-Months in the Rea..
BU
02/18Takeda Announces the First Six-Month Interim Analysis Results from Inspire
CI
02/16Ipsen - Cabometyx in combination with Opdivo demonstrated continued survival and qualit..
AQ
02/14Takeda Pharmaceutical Clocks Decline in Fiscal Q3 Attributable Profit
MT
1  2  3  4  5  6  7  8  9  10Next
Upcoming event on TAKEDA PHARMACEUTICAL COMPANY LIMITED